Navigation Links
Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
Date:5/7/2008

in cancer patients.

Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits Champions Biotechnology to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.

Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
2. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
5. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
6. Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration
7. World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment
8. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
9. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
10. Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays
11. Genetic Engineering and Biotechnology News (GEN) Blog: International Students in the United States - A Diminishing Pool of Talent for Biotech?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 2014 The 20 ambassadors representing the ... community issued the following statement on Facebook today regarding ... driving new funding specifically for ALS research: , “Who ... some ice would raise all this awareness and funding ... and on behalf of the entire ALS community, would ...
(Date:8/26/2014)... 26, 2014  ViveBio, LLC a leading provider ... and transportation, announced today that it has signed ... (LPS) of Knoxville, Tennessee ... the United States . ViveST is ... temperature dried biological specimen transport systems.  The technology ...
(Date:8/26/2014)... Genedata, a leading provider of advanced ... research, today announced the Genedata Screener® Global ... Asia, Europe, and North America during September 2014. ... research organizations will gather for annual User Group ... upcoming challenges in all areas of screening. This ...
(Date:8/26/2014)... Aug. 26, 2014 Albany Molecular Research Inc. ... William S. Marth , President and Chief Executive Officer ... Healthcare Conference on Monday, September 8, 2014 at 8:45 ... of the presentation can be accessed at AMRI,s Investor ... The webcast will be archived for 90 days following ...
Breaking Biology Technology:ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
... Switzerland and NUTLEY, N.J., Oct. 1 This ... leading business and,marketing publications, selected Roche out of ... Year." This marks the first time Roche has,received ... company,s focus on innovation-driven,healthcare as demonstrated by its ...
... 1 - New Product Under Development for ... in 28 European Countries DAIICHI SANKYO EUROPE GmbH ... new antihypertensive medication. It is a fixed combination,(CS-8663) of ... calcium antagonist Amlodipin. When approved, the new combination ...
... 1 Austria now has the most,consumer-friendly healthcare ... Consumer Index (EHCI). The EHCI compares all the ... Switzerland, from a,consumer-friendly point of view, measured by ... the Netherlands, with 2006 winner,France in third place. ...
Cached Biology Technology:Med Ad News Honors Roche as 'Company of the Year' 2Med Ad News Honors Roche as 'Company of the Year' 3DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin 2European Union has 'Three-Speed' Healthcare System - Many Countries Lagging in Reform 2
(Date:8/26/2014)... is pumping far more pollution into the atmosphere than ... the National Center for Atmospheric Research estimates that more ... in such fires, emitting gases and particles that can ... new study provides the first rough estimates, on a ... and mercury that are emitted by the fires. Such ...
(Date:8/26/2014)... Previous studies that have suggested an increased risk ... antidepressants during pregnancy may actually reflect the known ... In a study receiving advance online publication in ... Hospital (MGH) report that while a diagnosis ... the children of mothers prescribed antidepressants during pregnancy ...
(Date:8/26/2014)... Treatment of Animals (PETA) and the PETA International Science ... week at the 9th World Congress on Alternatives and ... on alternatives to the use of animals in research, ... problems with current laboratory oversight systems. , At the ... 28, 2014, PETA and PISC will present seven oral ...
Breaking Biology News(10 mins):Trash burning worldwide significantly worsens air pollution 2Trash burning worldwide significantly worsens air pollution 3Study calls into question link between prenatal antidepressant exposure and autism risk 2Study calls into question link between prenatal antidepressant exposure and autism risk 3
... of researchers from the LGC Chemical Metrology Laboratory in the ... up with a method to detect how the proportions of ... of protons and electrons but different numbers of neutrons) vary ... is to be able to use these methods to track ...
... have identified the locking mechanism that allows some neurons ... of genes that produce a critical cell-adhesion molecule involved ... The discovery -- captured with fluorescent imaging of excitatory ... studied in culture as they continued to develop -- ...
... (Nasdaq: AWRE ), a leading supplier of broadband ... first quarter ended March 31, 2009. Revenues for the ... 22% compared to $5.9 million in the same quarter last ... diluted net income per share in accordance with U.S. generally ...
Cached Biology News:Sulphur in just one hair could blow a terrorist's alibi 2Sulphur in just one hair could blow a terrorist's alibi 3Capturing the birth of a synapse 2Aware, Inc. Reports First Quarter 2009 Financial Results 2Aware, Inc. Reports First Quarter 2009 Financial Results 3Aware, Inc. Reports First Quarter 2009 Financial Results 4Aware, Inc. Reports First Quarter 2009 Financial Results 5Aware, Inc. Reports First Quarter 2009 Financial Results 6
... Western blotting is a commonly used ... Typically, protein samples are electrophoresed on SDS-PAGE ... nitrocellulose or nylon, where they are probed ... technologies, which allow reuse of Southern and ...
... ProXPRESS 2D Proteomic Imaging System, Basic Package ... a Wide Dynamic Range: The ProXPRESS 2D ... in imaging system for both proteomic and ... provides unparalleled flexibility, enabling the use of ...
... Introducing our Regulatory Edition of Molecular Imaging ... systems for life science research and drug ... compliance with U.S. Food and Drug Administrations ... 11 Electronic Records; Electronic Signatures [21 CFR ...
... OPA1-01009, OPEP-01009 is a 16 amino acid (amino acids 3-18) ... (DFF). The sequence of this peptide is (amino to ... S - V - K - L - R - ... R - K(18). This peptide may be used ...
Biology Products: